OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Weber on Toxicity Data From CheckMate-238 Trial in Melanoma

October 18th 2019

Jeffrey S. Weber, MD, PhD, shares toxicity data from the randomized, double-blind, phase III CheckMate-238 trial in resected stage III or IV melanoma.

Dr. Hong on Moving Tisotumab Vedotin to Frontline Therapy for Cervical Cancer

October 18th 2019

David S. Hong, MD, discusses the potential of moving tisotumab vedotin (HuMax-TF-ADC) to the frontline setting in cervical cancer.

Dr. Larson on the Impact of MRD on Treatment Decisions in Multiple Myeloma

October 17th 2019

Sarah M. Larson, MD, assistant professor of medicine, and director, Multiple Myeloma Program, University of California, Los Angeles, discusses the impact of minimal residual disease (MRD) on treatment decisions in multiple myeloma.

Dr. Anders on Sequencing Strategies in the Setting of HER2+ Brain Metastases

October 17th 2019

Carey Anders, MD, medical director, Brain and Spine Metastasis Program, and medical oncologist, Duke Cancer Institute, discusses sequencing strategies in the setting of HER2-positive breast cancer with brain metastases.

Dr. Borghaei on the Clinical Utility of PD-L1 in Advanced NSCLC

October 17th 2019

Hossein Borghaei, DO, MS, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, professor, Department of Hematology/Oncology, co-director, Immune Monitoring Facility, Lung Cancer and Mesothelioma TRDG member, and Gloria and Edmund M. Dunn Chair in Thoracic Oncology, Fox Chase Cancer Center, discusses the clinical utility of PD-L1 in advanced non–small cell lung cancer (NSCLC).

Dr. Weinberg on Targeted Therapies for Molecular Subsets of mCRC

October 17th 2019

Benjamin Weinberg, MD, discusses treatment strategies for patients with different molecular subtypes of metastatic colorectal cancer.

Dr. Smith on Using Venetoclax Versus Ibrutinib in CLL

October 17th 2019

Mitchell R. Smith, MD, PhD, discusses the use of venetoclax versus ibrutinib in patients with chronic lymphocytic leukemia.

Dr. Concepcion on Barriers to Genetic Testing in Community Urology Practices

October 17th 2019

Raoul S. Concepcion, MD, FACS, discusses barriers to genetic testing for patients with prostate cancer as identified by community urologists.

Dr. George on Investigational Agents Downstream of the Androgen Receptor in Prostate Cancer

October 17th 2019

Daniel J. George, MD, discusses investigational agents downstream of the androgen receptor in advanced prostate cancer.

Dr. Bourhis on the Rationale to Explore Debio 1143 in Head and Neck Cancer

October 17th 2019

Jean Bourhis, MD, PhD, Radiation Oncology, Centre Hospitalier Universitaire Vaudois, discusses the rationale to explore Debio 1143 in patients with head and neck cancer.

Dr. Lee on Trial Data Evaluating the Atezolizumab/Bevacizumab in Unresectable HCC

October 17th 2019

Michael S. Lee, MD, discusses trial data evaluating the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) in unresectable hepatocellular carcinoma.

Dr. Mato on the Use of Biosimilars in CLL

October 17th 2019

Anthony R. Mato, MD, MSCE, discusses the use of biosimilars in chronic lymphocytic leukemia.

Dr. Kuykendall on Choosing Ruxolitinib or Fedratinib in Myelofibrosis

October 17th 2019

Andrew T. Kuykendall, MD, discusses the use of ruxolitinib versus fedratinib in patients with myelofibrosis.

Dr. Schiller on Venetoclax and Glasdegib in AML

October 17th 2019

Gary J. Schiller, MD, discusses the benefits and challenges of using venetoclax and glasdegib in patients with relapsed/refractory acute myeloid leukemia.

Dr. Grande on the IMvigor130 Trial in Metastatic Urothelial Cancer

October 17th 2019

Enrique Grande, MD, discusses the design of the phase III IMvigor130 trial, which compared atezolizumab plus chemotherapy versus atezolizumab monotherapy (arm B) versus standard chemotherapy plus placebo in patients with previously untreated locally advanced or metastatic urothelial carcinoma.

Dr. Gerson on Targeted Therapy Versus Chemotherapy in CLL

October 16th 2019

James N. Gerson, MD, discusses the emergence of targeted therapy in chronic lymphocytic leukemia.

Dr. Lee on the Results of the ENTRATA Trial in Advanced RCC

October 16th 2019

Chung-Han Lee, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of the phase II ENTRATA trial in advanced renal cell carcinoma (RCC).

Dr. Bhave on Promising Anti-HER2 Agents in HER2+ Breast Cancer

October 16th 2019

Manali Bhave, MD, an assistant professor in the Department of Hematology and Medical Oncology at Winship Cancer Institute, Emory University School of Medicine, discusses promising anti-HER2 agents in metastatic HER2-positive breast cancer.

Dr. Nasri on Risk Stratification in Osteosarcoma

October 16th 2019

Elham Nasri, MD, fellow, Bone and Soft Tissue Pathology, University of Florida, discusses risk stratification in osteosarcoma.

Dr. Bekaii-Saab on the Addition of Atezolizumab to Capecitabine/Bevacizumab in MSS mCRC

October 15th 2019

Tanios S. Bekaii-Saab, MD, FACP, discusses the results of the phase II BACCI trial evaluating the addition of atezolizumab to capecitabine plus bevacizumab versus capecitabine/bevacizumab plus placebo in patients with microsatellite stable metastatic colorectal cancer.